Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Personality & Trait Factors

Esketamine for Personality & Trait Factors

2 papers and 0 clinical trials exploring esketamine as a treatment for personality & trait factors.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 10 million adults in the UK suffer from a personality disorder.

Personality & Trait Factors

Psychedelic research is increasingly examining the interplay between personality traits and therapeutic outcomes in various mental health conditions. Recent studies highlight how certain personality traits may influence the efficacy of psychedelic treatments, particularly in managing disorders like depression and anxiety.

Full Personality & Trait Factors profile

Academic Research

2 papers
Open Accessindividual

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study

This qualitative interview study (n=17) of those receiving esketamine (35-210mg/70kg, 12x over 6w) for depression explores patients' experiences. Findings reveal highly variable effects of ketamine with common psychological distress, and central themes include perceptual effects, detachment, stillness and openness, mystical-type effects, fear and anxiety, feeling hungover and tired, and a neutralizing mood effect post-session. While patients reported several esketamine effects with psychotherapeutic potential such as increased openness, detachment, and mystical-type experiences, the study identifies a need for additional support due to the frequency and severity of the perceived distress during the treatment.

Published
May 24, 2023
Journal
Psychopharmacology
Authors
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Vermetten, E., Kamphuis, J., van den Brink, W., Schoevers, R. A.
Open Accessmeta

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression

This article (2015) examines the advantages and applications of intranasal drug delivery, with a particular focus on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression. The article contrasts intranasal delivery to oral and sublingual delivery methods, which are less effective with regards to their bioavailability, crossing of the blood-brain-barrier, and rapid onset of drug effects.

Published
January 1, 2015
Journal
Journal of Clinical Psychiatry
Authors
Andrade, C.

Clinical Trials

0 trials

No clinical trials have been tagged with both Esketamine and Personality & Trait Factors yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Esketamine papers Search all Personality & Trait Factors trials Full Esketamine profile Full Personality & Trait Factors profile